Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) was the target of unusually large options trading on Friday. Stock investors purchased 29,762 call options on the company. This is an increase of approximately 131% compared to the typical daily volume of 12,905 call options.
In related news, CFO Paul Herendeen purchased 24,000 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Tuesday, March 14th. The shares were acquired at an average price of $10.72 per share, with a total value of $257,280.00. Following the completion of the transaction, the chief financial officer now directly owns 174,000 shares of the company’s stock, valued at approximately $1,865,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Schutter Richard U. De purchased 10,000 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Wednesday, March 15th. The shares were bought at an average cost of $10.80 per share, for a total transaction of $108,000.00. Following the transaction, the director now directly owns 25,190 shares of the company’s stock, valued at $272,052. The disclosure for this purchase can be found here. Insiders have purchased 3,034,000 shares of company stock worth $32,825,280 in the last three months. 16.37% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the stock. US Bancorp DE increased its stake in shares of Valeant Pharmaceuticals Intl by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 3,361 shares during the last quarter. LeJeune Puetz Investment Counsel LLC purchased a new stake in shares of Valeant Pharmaceuticals Intl during the fourth quarter valued at approximately $123,000. Ray Gerald L & Associates Ltd. purchased a new stake in shares of Valeant Pharmaceuticals Intl during the third quarter valued at approximately $246,000. Warren Averett Asset Management LLC purchased a new stake in shares of Valeant Pharmaceuticals Intl during the third quarter valued at approximately $246,000. Finally, Frontier Wealth Management LLC purchased a new stake in shares of Valeant Pharmaceuticals Intl during the fourth quarter valued at approximately $149,000. Hedge funds and other institutional investors own 64.34% of the company’s stock.
VRX has been the topic of a number of analyst reports. Rodman & Renshaw downgraded Valeant Pharmaceuticals Intl from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 31st. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price objective (down previously from $21.00) on shares of Valeant Pharmaceuticals Intl in a report on Thursday, March 23rd. Guggenheim reissued a “buy” rating on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, February 7th. Piper Jaffray Companies reissued an “outperform” rating and set a $10.00 price objective on shares of Valeant Pharmaceuticals Intl in a report on Friday, April 14th. Finally, BMO Capital Markets cut their price objective on Valeant Pharmaceuticals Intl from $19.00 to $15.00 and set a “market perform” rating on the stock in a report on Tuesday, March 14th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $24.68.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 4.17% during trading on Friday, hitting $8.51. The stock had a trading volume of 28,008,886 shares. Valeant Pharmaceuticals Intl has a 52-week low of $8.36 and a 52-week high of $38.50. The stock has a 50 day moving average of $10.73 and a 200 day moving average of $15.45. The firm’s market cap is $2.96 billion.
Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its quarterly earnings data on Tuesday, February 28th. The specialty pharmaceutical company reported $1.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.06. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.34 billion. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. The company’s revenue was down 12.9% on a year-over-year basis. During the same period last year, the firm earned $1.55 EPS. On average, equities analysts anticipate that Valeant Pharmaceuticals Intl will post $3.89 EPS for the current year.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.